118 results about "Conjugated vaccines" patented technology

The invention relates to a bacterial polysaccharide-protein conjugate vaccine with immunogenicity, in particular to a conjugate vaccine which is formed by connecting a recombinant rotavirus protein with a bacterial polysaccharide by using a covalent bond, a nucleotide sequence for coding the recombinant rotavirus protein, a recombinant expression system, a protein expressed by the recombinant expression system, a preparation method of the conjugate vaccine and a pneumococcus polysaccharide-recombinant rotavirus protein conjugate vaccine. The bacterial polysaccharide is connected with a recombinant rotavirus surface protein through a covalent bond. The recombinant rotavirus protein is selected from a partial or complete amino acid sequence of a P-gene rotavirus protein and a partial or complete amino acid sequence of a G-gene rotavirus protein.

The invention provides vaccines against Neisseria meningitidis, pneumococcus and DTPa/w. In particular, it provides vaccines based on conjugated capsular saccharides from multiple meningococcal and/or pneumococcal serogroups. It further provides vaccine administration schemes for the immunisation of human patients with two or more of these vaccines.

The invention provides a multivalent pneumococcal capsular polysaccharide composition as well as a preparation method and application thereof. The multivalent pneumococcal capsular polysaccharide composition contains a serotype 6A and at least one extra serotype selected from the group consisting of 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. The multivalent pneumococcal capsular polysaccharide composition provided by the invention can be used for inducing an organism to generate humoral immunity, can generate a relatively good protecting effect for infectious diseases caused by the 24 common serotype pneumococcuses and is wide in immunity coverage rate and better in effect as comparison with various existing pneumococcal polysaccharide vaccines and conjugate vaccines sold on the market.

The present invention provides an optimal formulation of multiple serotype Streptococcus pneumoniae conjugate vaccines.

The present invention relates, at least in part, to novel and improved flow-through purification processes for separating large biomolecules, such as, for example, encapsulated viruses, virus-like particles and conjugate vaccines from one or more contaminants in a sample, where the process employs the use of at least one population of a solid porous particle which comprises a minimized external surface area per unit volume of the particles and an internal surface area per unit volume which is not decreased by more than 25% relative to a population of a similar particle which does not have a minimized external surface area.

The present invention discloses a Haemophilus influenzac type B polysaccharide conjugate vaccine preparation method, which comprises: A, preparing a Haemophilus influenzac type B polysaccharide extract (PRP), adopting ultrapure water or water for injection to dissolve the PRP polysaccharide at a room temperature until achieving a concentration of 20 mg/ml, adding CDAP according to a mass ratio of PRP to CDAP of 1, maintaining for 1.5 min, adjusting the pH value to 9.5 with 0.3 M NaOH, maintaining for 3 min, adding a solid ADH according to a mass ratio of ADH to the PRP polysaccharide of 4:1, adjusting the pH value to 9.5 with 0.3 M NaOH, maintaining for 1 h, and carrying out dialysis at a temperature of 2-8 DEG C with 0.2 M NaCl; and B, mixing the obtained PRP-AH and a 20 mg/ml TT solution according to a mass ratio of 1:2, adjusting the pH value to 5.0 with 0.1 M HCL, adding a solid EDAC according to a mass ratio of EDAC to PRP of 10:1, maintaining the pH value of 5.0 for 60 min at a room temperature, adjusting the pH value to 7.5 with 0.3 M NaOH, and carrying out a reaction for 30 min.

The invention provides a polyvalent pneumococcus polysaccharide conjugate vaccine and a preparation method thereof. For a polysaccharide-protein conjugate with immunogenicity, polysaccharide coming from streptococcus pneumoniae and protein form the conjugate, wherein the polysaccharide belongs to capsular polysaccharide with the serotype being 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 16F, 17F, 18C, 19A, 19F, 20, 20F, 23A, 23F and 33F. For the conjugate provided by the invention, the serum coverage rate achieves 90% or above, and a protection effect can be generated on people of 2 months or older.

The invention describes a method for preparing a meningitis polysaccharide conjugate vaccine. The meningitis polysaccharide conjugate vaccine is developed based on the method. The method comprises the following steps: (1) activating meningococcus polysaccharides by cyanogen bromide, then deriving the meningococcus polysaccharides which are activated by the cyanogen bromide by ethanediamine, finally deriving the polysaccharides by a reagent which is of a structure of succinimidyl ester-R-maleimide; (2), sulfhydrylating carrier proteins; (3) combining the derived meningococcus polysaccharides with the sulfhydrylated carrier proteins. As conjugation bridges between the meningococcus polysaccharides and the carrier proteins are very long, the spatial shielding effect of the carrier proteins on the antigenic epitopes of the polysaccharides is reduced, and the original immunization property of the polysaccharide conjugate vaccine is improved.

The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.

The invention discloses a vaccine for preventing and treating diseases caused by Acinetobacter baumannii and a preparation method thereof. The vaccine for preventing and treating the diseases caused by the Acinetobacter baumannii provided by the invention has an active component which is an Acinetobacter baumannii glycoprotein obtained through glycosylation of a protein composed of bases from site20 to site 156 of SEQ ID No. 1 or bases from site 1 to site 156 of SEQ ID No. 1. According to the invention, Acinetobacter baumannii glycoprotein modified rCTB4573 prepared by a genetic engineering method is used for preparation of an Acinetobacter baumannii glycoprotein protein conjugate vaccine; uniformity of the vaccine can be improved; production efficiency of the vaccine is improved; the cost is reduced; extensive application prospect is achieved; and the vaccine can be used for preventing the diseases caused by pathogenic Acinetobacter baumannii.

The invention discloses a low-dose multivalent conjugated vaccine composition and application. The low-dose multivalent conjugated vaccine composition comprises group-A meningococcus capsular polysaccharide-carrier protein conjugate with group-A meningococcus capsular polysaccharide between 2.0 and 4.8mu g, group-C meningococcus capsular polysaccharide-carrier protein conjugate with group-C meningococcus capsular polysaccharide between 2.0 and 4.8mu g, group-Y meningococcus capsular polysaccharide-carrier protein conjugate with group-Y meningococcus capsular polysaccharide between 2.0 and 4.8mu g, group-W135 meningococcus capsular polysaccharide-carrier protein conjugate with group-W135 meningococcus capsular polysaccharide between 2.0 and 4.8mu g, and type-B haemophilus influenzae capsular polysaccharide-carrier protein conjugate with type-B haemophilus influenzae capsular polysaccharide between 2.0 and 4.8mu g. According to the low-dose multivalent conjugated vaccine composition, the production cost can be reduced, and the content of impurities with toxic and side effects in the product can be reduced, so that the safety of the vaccine can be improved, the number of vaccination times for infants can be reduced, and the vaccination omission rate can be reduced.

The present invention relates, e.g., to a glycoconjugate composition comprising one or more polysaccharide types from a cell wall polysaccharide preparation from B. pumilus Sh 18, or variants thereof. Also disclosed are antibodies generated against the glycoconjugates, and methods of using the glycoconjugates and antibodies. An antimultiorganism vaccine which reacts against at least Haemophilus influenzae type a, Haemophilus influenzae type b, Staphylococcus aureus, and Staphylococcus epidermidis, is disclosed.

The invention discloses a process for activating a Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccine, which comprises the following steps of: A, preparing Hib polysaccharide; B, dissolving 1-Cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) by using acetonitrile into a solution; C, preparing the Hib polysaccharide into a solution; D, adding the CDAP solution to the Hib polysaccharide solution, and stirring for 2-5 minutes at the room temperature; E, dissolving adipic dihydrazide (ADH) by using NaHCO3 into a solution, adding the ADH solution to a mixed solution, and stirring for 0.5-2 hours at the room temperature; and F, collecting eluent of the void volume from a loading solution after the reaction is ended at a SephadexG-25 gel chromatography column balanced in advance by water for injection, and performing freeze drying to obtain a Hib polysaccharide-ADH derivative. The process for activating the Hib polysaccharide conjugate vaccine has the beneficial effects that the quality index of the prepared Hib polysaccharide-ADH can reach the industrial standard, and moreover, the safe and nontoxic CDAP is adopted to serve as an activating agent instead of cyanogen bromide which is greatly harmful to human and environment, and therefore, the safety is enhanced, and the harm to the human and the environment are avoided.

The invention relates to a method for determining the content of the polysaccharide of each group of meningococcus polysaccharide conjugate vaccine finished products and belongs to the technical field of biology. The method comprises the following steps of: treating by using protease K during preparation of a detection product sample, wherein the total size of an enzymolysis reaction system is 420 mu l; and by using the total size as reference, adding the protease K, a protease K buffer solution which occupies one tenth of the total size and an ultra-filtration concentrated solution which occupies one sixth of the total size, uniformly mixing the protease K, the protease K buffer solution and the ultra-filtration concentrated solution, and then incubating, wherein the addition amount of the protease K is two to eight times of the content of proteins in the enzymolysis reaction system. By adoption of the method, influence of each group of conjugate carrier proteins on immunoelectrophoresis is eliminated, an appropriate detection system for detecting the polysaccharide of each of more than four groups of meningococcus polysaccharide conjugate vaccine finished products is established, and the content of the polysaccharide of each of more than four groups of meningococcus polysaccharide conjugate vaccine finished products can be accurately and quickly determined. The method has the characteristics of high durability, high accuracy and high precision. A method for evaluating the quality of meningococcus polysaccharide conjugate vaccine is established.

The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O5 polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

The invention is based on the use of a basic reagent under basic conditions to separate conjugated saccharide from unconjugated components in a sample, e.g. a vaccine, by precipitation of the conjugated saccharide. The invention allows rapid and quantitative separation of conjugated and conjugated components, which may be exploited in analytical methods for quantifying unconjugated saccharide or carrier. Therefore, the separation of conjugated and unconjugated components using the invention may be advantageously combined with a quantitative saccharide or carrier analysis to provide improved quality control for conjugate vaccines.